REGULATION OF BRAIN NEUROTRANSMITTER SYNTHESIS
脑神经递质合成的调节
基本信息
- 批准号:6540087
- 负责人:
- 金额:$ 33.37万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2000
- 资助国家:美国
- 起止时间:2000-06-05 至 2004-05-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Glutamate is the most widely used excitatory neurotransmitter in the nervous system. Certain diseases and neurodegenerative disorders are thought to involve disturbances of the glutamatergic systems of the brain or retina. The goal of this proposal is to understand the mechanisms that regulate glutamate levels in the nervous system. Considerable evidence indicates that glial cells rapidly internalize glutamate released by neurons during neurotransmission converting it to glutamine before releasing it back to neurons in the glutamate/glutamine cycle. However, it is now clear that possibly as much as 50 percent of the glutamate taken up by the glia is actually converted to pyruvate and lactate. Therefore, the nervous system must regenerate the lost carbon by carboxylation of pyruvate catalyzed by the anaplerotic enzyme pyruvate carboxylase (PC) which is found is astroglia. Second, it now appears that rather than ammonia the essential branched chain amino acids (BCAA) are needed to provide sufficient alpha-amino nitrogen for optimal rates of de novo glutamate synthesis. Indeed, it is our hypothesis that the BCAA and branched chain aminotransferase isoenzymes (cytosolic BCATc, mitochondrial BCATm) participate in a nitrogen shuttle whereby the glial BCATm and neuron specific BCATc act in series to transfer nitrogen from neurons to astrocytes. The aims of this proposal are designed to understand the mechanisms that regulate glutamate levels in the nervous system and test the BCAA shuttle hypothesis. 1) We will develop methods to simultaneously measure the rate of de novo glutamate synthesis and the rate of glutamate glutamine cyclin in the ex vivo retina and in brain in vivo and correlate the influence of neuronal activity with flux. Both H14CO3 and 13C NMR spectroscopy will be used in vivo for the kinetic analysis. 2) The function of the BCAT isoenzymes in regulating glutamate synthesis and brain neurotransmitter pool sizes will be quantified in vivo in brain and ex vivo in the retina. The hypothesis that the neuroactive drug gabapentin acts via specific inhibition of cytosolic BCATc will be tested. 3) The degree of control exerted by the anaplerotic enzyme pyruvate carboxylase (PC) relative to that of the BCAT isoenzymes will be assessed. Antisense technology will be used to vary enzyme levels in vivo. Data will be analyzed using control strength theory to determine the relative control strength of the BCAT and PC on the pathways of de novo glutamate synthesis. Finally, understanding the mechanisms that regulate glutamate synthesis will increase our knowledge of certain disease processes and may allow for future generation of novel therapeutic compounds.
谷氨酸是神经系统中应用最广泛的兴奋性神经递质。某些疾病和神经退行性疾病被认为与大脑或视网膜的谷氨酸能系统紊乱有关。这项提议的目的是了解调节神经系统中谷氨酸水平的机制。大量证据表明,神经胶质细胞在神经传递过程中迅速内化神经元释放的谷氨酸,将其转化为谷氨酰胺,然后在谷氨酸/谷氨酰胺循环中释放回神经元。然而,现在很清楚的是,可能有多达50%的谷氨酸被神经胶质细胞吸收,实际上转化为丙酮酸和乳酸。因此,神经系统必须通过丙酮酸羧化酶(即星形胶质细胞中的丙酮酸羧化酶)催化的丙酮酸羧化来再生丢失的碳。其次,现在看来,需要必需的支链氨基酸(BCAA)而不是氨来提供足够的α -氨基氮,以达到最佳的谷氨酸从头合成速率。事实上,我们的假设是BCAA和支链转氨酶同工酶(细胞质BCATc,线粒体BCATm)参与了一个氮传递过程,其中胶质BCATm和神经元特异性BCATc串联起作用,将氮从神经元转移到星形胶质细胞。本研究旨在了解调节神经系统谷氨酸水平的机制,并验证BCAA穿梭假说。1)我们将开发同时测量离体视网膜和大脑中谷氨酸新合成速率和谷氨酸谷氨酰胺周期素速率的方法,并将神经元活动与通量的影响联系起来。H14CO3和13C核磁共振光谱将在体内用于动力学分析。2) BCAT同工酶调节谷氨酸合成和脑神经递质池大小的功能将在体内和离体视网膜中量化。神经活性药物加巴喷丁通过特异性抑制胞浆BCATc起作用的假设将被测试。3)对比BCAT同工酶的抑菌效果,评价丙酮酸羧化酶(PC)抑菌效果。反义技术将用于改变体内的酶水平。利用控制强度理论分析数据,确定BCAT和PC对从头合成谷氨酸途径的相对控制强度。最后,了解调节谷氨酸合成的机制将增加我们对某些疾病过程的认识,并可能使未来一代新的治疗化合物成为可能。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SUSAN M HUTSON其他文献
SUSAN M HUTSON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SUSAN M HUTSON', 18)}}的其他基金
相似海外基金
Novel pediatric anticonvulsants for nerve agents
用于神经毒剂的新型儿科抗惊厥药
- 批准号:
10004277 - 财政年份:2020
- 资助金额:
$ 33.37万 - 项目类别:
Novel pediatric anticonvulsants for nerve agents
用于神经毒剂的新型儿科抗惊厥药
- 批准号:
10475298 - 财政年份:2020
- 资助金额:
$ 33.37万 - 项目类别:
Novel Water-Soluble Adjunct Anticonvulsants for Nerve Agents
用于神经毒剂的新型水溶性辅助抗惊厥药
- 批准号:
10013749 - 财政年份:2020
- 资助金额:
$ 33.37万 - 项目类别:
Novel pediatric anticonvulsants for nerve agents
用于神经毒剂的新型儿科抗惊厥药
- 批准号:
10693904 - 财政年份:2020
- 资助金额:
$ 33.37万 - 项目类别:
Study on how anticonvulsants affect car driving
抗惊厥药如何影响汽车驾驶的研究
- 批准号:
20K17977 - 财政年份:2020
- 资助金额:
$ 33.37万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Novel Water-Soluble Adjunct Anticonvulsants for Nerve Agents
用于神经毒剂的新型水溶性辅助抗惊厥药
- 批准号:
10266034 - 财政年份:2020
- 资助金额:
$ 33.37万 - 项目类别:
Novel Water-Soluble Adjunct Anticonvulsants for Nerve Agents
用于神经毒剂的新型水溶性辅助抗惊厥药
- 批准号:
10475109 - 财政年份:2020
- 资助金额:
$ 33.37万 - 项目类别:
Novel pediatric anticonvulsants for nerve agents
用于神经毒剂的新型儿科抗惊厥药
- 批准号:
10248384 - 财政年份:2020
- 资助金额:
$ 33.37万 - 项目类别:
Prevention of neuropathic pain by antidepressants and anticonvulsants: in vivo patch-clamp analysis
抗抑郁药和抗惊厥药预防神经性疼痛:体内膜片钳分析
- 批准号:
24592355 - 财政年份:2012
- 资助金额:
$ 33.37万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Anticonvulsants, ischemic seizures and regeneration in the immature brain
抗惊厥药、缺血性癫痫发作和未成熟大脑的再生
- 批准号:
8492175 - 财政年份:2009
- 资助金额:
$ 33.37万 - 项目类别:














{{item.name}}会员




